Radiomics predicting immunohistochemical markers in primary hepatic carcinoma: Current status and challenges.

Primary hepatic carcinoma, comprising hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined hepatocellular cholangiocarcinoma (cHCC-CCA), ranks among the most common malignancies worldwide. The heterogeneity of tumors is a primary factor impeding the efficacy of treatments for primary hepatic carcinoma. Immunohistochemical markers may play a potential role in characterizing this heterogeneity, providing significant guidance for prognostic analysis and the development of personalized treatment plans for the patients with primary hepatic carcinoma.

Enhancing Axillary Lymph Node Diagnosis in Breast Cancer with a Novel Photoacoustic Imaging-Based Radiomics Nomogram: A Comparative Study of Peritumoral Regions.

Rationale And Objectives: This study aims to assess the predictive ability of photoacoustic (PA) imaging-based radiomics combined with clinical characteristics for axillary lymph node (ALN) status in early-stage breast cancer patients and to compare performance in different peritumoral regions.

Methods: This study involved 369 patients from Shenzhen People's Hospital, divided into a training set of 295 and a testing set of 74. PA imaging data were collected from all participants, and radiomics analysis was performed on intratumoral and various peritumoral regions.

Ultrasound Radiomics for the Prediction of Breast Cancers with HER2-Zero, -Low, and -Positive Status: A Dual-Center Study.

Purpose: To assess whether gray-scale ultrasound (US) based radiomic features can help distinguish HER2 expressions (ie, HER2-overexpressing, HER2-low-expressing, and HER2-zero-expressing) in breast cancer.

Materials And Methods: This retrospective study encompassed female breast cancer patients who underwent US examinations at two distinct centers from February 2021 to July 2023. Tumor segmentation and radiomic feature extraction were performed on grayscale US images.

Integrated nomogram to predict HER2 expression in breast tumor: Clinical, Ultrasound, and Photoacoustic imaging approaches.

Background: HER2 is a key biomarker for breast cancer treatment and prognosis. Traditional assessment methods like immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are effective but costly and time-consuming. Our model incorporates these methods alongside photoacoustic imaging to enhance diagnostic accuracy and provide more comprehensive clinical insights.